Immunovant (IMVT) Capital Expenditures (2019 - 2026)
Immunovant's Capital Expenditures was $8,000 in fiscal Q4 2026 (quarter ended Mar 31, 2026), down 96.0% from $201,000 a year earlier.
Powered by 
Analysis
Immunovant (IMVT) Capital Expenditures (2019 - 2026) Analysis & Trends
From fiscal Q2 2020 onward, Immunovant has reported Capital Expenditures for 24 quarters.
- Capital Expenditures shows a five-year compound annual growth rate of -48.0% (FY2021 to FY2026).
- In earlier fiscal years, Capital Expenditures was $759,000 in FY2025 (+110.8%), $360,000 in FY2024 (+82.7%), $197,000 in FY2023 (-22.4%) and $254,000 in FY2022 (+21.0%).
- Compared with a year earlier, Capital Expenditures was higher in four of the last five quarters, with growth averaging 151.3%.
- The best year-over-year quarter for Capital Expenditures over five years was fiscal Q4 2024 (growth of 476.9%); the worst was fiscal Q4 2026 (a decline of 96.0%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,135.99 Bn | 1,104.58 Bn | 19.71 Bn | 2.93 Bn |
| 2 | Johnson & Johnson | 616.90 Bn | 535.42 Bn | 17.26 Bn | 1.32 Bn |
| 3 | AbbVie | 501.56 Bn | 474.68 Bn | 12.70 Bn | 322.00 Mn |
| 4 | Merck | 367.41 Bn | 321.79 Bn | 12.21 Bn | 893.00 Mn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | 321.00 Mn |
| 6 | Astrazeneca | 261.45 Bn | 235.13 Bn | 12.86 Bn | 1.86 Bn |
| 7 | Amgen | 236.48 Bn | 191.88 Bn | 7.24 Bn | 513.00 Mn |
| 8 | Gilead Sciences | 190.56 Bn | 164.76 Bn | 6.22 Bn | 140.00 Mn |
| 9 | Pfizer | 169.46 Bn | 116.11 Bn | 10.94 Bn | 533.00 Mn |
| 10 | Immunovant | 5.82 Bn | 2.60 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2025 | 201,000.00 |
| Dec 31, 2024 | 180,000.00 |
| Sep 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Jun 30, 2023 | 45,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Dec 31, 2022 | 98,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Mar 31, 2022 | 118,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 44,000.00 |
| Jun 30, 2021 | 18,000.00 |
| Mar 31, 2021 | 95,000.00 |
| Dec 31, 2020 | 29,000.00 |
| Sep 30, 2020 | 39,000.00 |
API Access
Immunovant Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IMVT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "IMVT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IMVT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();